ArticlePloS one2026
Alaska pollock protein as a functional dietary source for promoting skeletal muscle hypertrophy and lipid metabolic remodeling.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alaska pollock protein (APP) promotes skeletal muscle hypertrophy, particularly in fast-twitch fibers. Using a time-controlled feeding model, plasma collected 90 min after APP intake markedly enhanced C2C12 myotube hypertrophy and contractility. At this time point, plasma glucagon-like peptide-1 levels were significantly elevated, suggesting the involvement of circulating factors associated with APP intake. Proteomic and lipidomic analyses of skeletal muscle identified 2302 proteins and 538 lipids, and revealed pronounced remodeling of lipid metabolism, including a 127% increase in docosahexaenoic acid (DHA)-containing phospholipids in hypertrophied fast-twitch fibers, partially resembling endurance training adaptations. APP also upregulated adipose triglyceride lipase and hormone-sensitive lipase in the skeletal muscle, indicating enhanced lipid catabolism. Although APP contained only trace amounts of DHA (~0.008% of the diet), this level was substantially lower than the dietary DHA level previously reported to alter tissue lipid composition. Therefore, APP-derived DHA was unlikely to be the primary driver of the observed phenotype. Together, these findings indicate that APP functions primarily as a high-quality protein source that promotes muscle anabolic responses and is associated with remodeling of lipid metabolic pathways, thereby potentially contributing to a circulating environment favorable for skeletal muscle hypertrophy and metabolic regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.